Concentrations of TGF-β (white box) and IL-17 (hatched box) in the (A) PF collected from control subjects and women with endometriosis, (B) their distribution based on the revised ASRM staging of endometriosis, and (C) based on the phases of the menstrual cycle. The boxes represent the IQRs and horizontal lines in the boxes represent median values. (A) PF concentrations of both TGF-β and IL-17 were significantly higher in women with endometriosis than in control subjects. *P < 0.0001; **P = 0.004. (B) Women with stage I-II endometriosis: *P < 0.0001 vs control for TGF-β; **P = 0.005 vs control for IL-17. Women with stage III-IV endometriosis: *P < 0.0001 vs control for TGF-β; **P = 0.001 vs control for IL-17. (C) PF levels of TGF-β in women with endometriosis: *P = 0.02 between secretory phase and proliferative phase: *P = 0.01 between menstrual phase and proliferative phase; PF levels of IL-17 in women with endometriosis: **P = 0.01 between secretory phase and proliferative phase: **P = 0.009 between menstrual phase and proliferative phase.